Latest stories on MXCT
Stifel reiterates Buy on MaxCyte stock, cites Q3 growth momentum
Investing.com Analyst Ratings63 · neutralanalyst
MaxCyte outlines at least $34.5M 2026 revenue as it plans Akron Bio deal to accelerate profitability
Seeking Alpha67 · bullishm&a
MaxCyte, Inc. (MXCT) Q3 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
MaxCyte Inc (MXCT) (Q3 2026) Earnings Call Highlights: Revenue Surges 49% as Accron Acquisition Nearly Doubles Scale
GuruFocus74 · bullishearnings
MaxCyte (MXCT) Q3 2026 Earnings Call Transcript
The Motley Fool63 · neutralearnings
MaxCyte (MXCT) Shares Drop Over 10% After $151.8M Akron BioProducts Acquisition Announcement
GuruFocus34 · bearishm&a
MaxCyte falls after $151.8M deal to buy Akron Bio for cash and stock
Seeking Alpha42 · neutralm&a
MaxCyte Inc Reports Strong Q3 2026 Revenue of $10.2 Million, Surpassing Estimates of $7.48 Million
GuruFocus74 · bullishearnings
MaxCyte Reports Strong Third-Quarter Revenue Growth and Narrower Loss
TipRanks58 · neutralearnings
MAXCYTE, INC. (MXCT) files 8-K
SEC 8-K50 · neutralgeneral
MaxCyte beats Q3 EPS and revenue estimates, issues FY revenue guidance above consensus
Seeking Alpha74 · bullishearnings
MaxCyte Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue Guidance
StockTitan58 · neutralearnings
MaxCyte to Participate in Three Upcoming Investor Conferences
GlobeNewswire53 · neutralproduct/pr
MaxCyte to Participate in Three Upcoming Investor Conferences
Business Insider52 · neutralproduct/pr
MXCT jumps after preliminary Q3 revenue points to a guidance raise to about $34 million
MarketChameleon74 · bullishearnings
MaxCyte stock rallies on initial Q3 revenue, higher FY26 outlook
Seeking Alpha74 · bullishearnings
MaxCyte raises FY26 revenue view to $34M from $30M-$32M, consensus $31.45M
The Fly67 · bullishearnings
MaxCyte reports preliminary Q3 revenue $8.1M, consensus $7.02M
The Fly64 · neutralearnings
MAXCYTE, INC. (MXCT) files 8-K
SEC 8-K50 · neutralgeneral
MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
GlobeNewswire64 · neutralearnings
MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
Business Insider64 · neutralearnings
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
Business Insider55 · neutralgeneral
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Insider50 · neutralgeneral
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire50 · neutralgeneral